Findings

What do systematic reviews say?

48 questions · 48 findings · 9 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 8.3%GRADE not reported 1 · 2.1%Very low 6 · 12.5%Low 20 · 41.7%Moderate 14 · 29.2%High 3 · 6.3%

EGFR tyrosine kinase inhibitor (TKI) vs observation

Progression‐free survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) changes progression‐free survival compared with observation alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 1.05 [0.9, 1.23]
1 study · 835 participants
Very low

EGFR tyrosine kinase inhibitor (TKI) vs observation

Quality of life · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 835 participants
Very low

Afatinib vs chemotherapy alone

Overall survival · EGFR M+ patients with NSCLC

Afatinib showed no clear difference in overall survival compared with chemotherapy (high certainty).

1 finding from 1 review

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
HR 0.91 [0.75, 1.1]
2 studies · 709 participants
High

Afatinib vs chemotherapy alone

Progression‐free survival · EGFR M+ patients with NSCLC

Afatinib leads to lower progression‐free survival compared with chemotherapy (high certainty).

1 finding from 1 review

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
HR 0.42 [0.34, 0.53]
2 studies · 709 participants
High

Intervention not reported

Primary cure (remission) · women withe low‐risk GTN

The intervention probably leads to lower primary cure (remission) (moderate certainty).

1 finding from 1 review

First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia 2016 · Cochrane Headline outcomes only
RR 0.65 [0.57, 0.75]
6 studies · 577 participants
Moderate

Intervention not reported

Severe adverse events (≥ grade 3) · women withe low‐risk GTN

The intervention showed no clear difference in severe adverse events (≥ grade 3) (low certainty).

1 finding from 1 review

First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia 2016 · Cochrane Headline outcomes only
RR 0.35 [0.08, 1.66]
5 studies · 515 participants
Low

Intervention not reported

Nausea · women withe low‐risk GTN

The intervention showed no clear difference in nausea (moderate certainty).

1 finding from 1 review

First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia 2016 · Cochrane Headline outcomes only
RR 0.61 [0.29, 1.26]
4 studies · 466 participants
Moderate

Intervention not reported

Alopecia · women withe low‐risk GTN

1 finding from 1 review

First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low